The utility of spirometry in the diagnosis of reversible airways obstruction
- PMID: 1350971
- DOI: 10.1378/chest.101.6.1577
The utility of spirometry in the diagnosis of reversible airways obstruction
Abstract
Patients with suspected reversible airways obstruction (RAO) sometimes report subjective benefit after bronchodilator treatment despite no objective spirometric improvement. One possible explanation for this is improvement in volume-related or plethysmographic parameters in the absence of spirometric improvement. One hundred patients with RAO were assessed before and after inhaled bronchodilator to determine the prevalence of improvement by plethysmographic parameters in the absence of improvement in spirometric parameters. Spirometry alone (FEV1, FVC, and FEF25-75%) identified reversibility of airflow limitation in 82 patients. Reversibility was identified by body plethysmography (specific conductance [SGaw], thoracic gas volume [TGV], and isovolume maximum expiratory flow rates [IVMEF]) in 15 of the remaining patients. The percent predicted FEF25-75% at baseline was higher in patients who required plethysmography to identify reversibility, but could not be used to predict the lack of a spirometric response for any individual patient. We conclude that spirometry alone fails to identify reversibility in approximately 15 percent of patients, and that most of these patients can be identified by additional plethysmographic measurements of volume-related parameters. At any one point in time, multiple tests must be used together to adequately identify the majority of patients with reversible airways obstruction. Improvement in volume-related parameters may explain why some patients with RAO improve subjectively with bronchodilators but show no spirometric improvement.
Similar articles
-
Plethysmographic parameters in the assessment of reversibility of airways obstruction in patients with clinical emphysema.Chest. 1993 Aug;104(2):467-70. doi: 10.1378/chest.104.2.467. Chest. 1993. PMID: 8339635
-
Alternative functional criteria to assess airflow-limitation reversibility in asthma.Rev Port Pneumol (2006). 2015 Mar-Apr;21(2):69-75. doi: 10.1016/j.rppnen.2014.08.002. Epub 2015 Feb 7. Rev Port Pneumol (2006). 2015. PMID: 25926369
-
Evaluation of the magnitude of the bronchodilator response in children and adolescents with asthma.Chest. 2005 Feb;127(2):530-5. doi: 10.1378/chest.127.2.530. Chest. 2005. PMID: 15705992 Clinical Trial.
-
Response to bronchodilators.Clin Chest Med. 1989 Jun;10(2):155-64. Clin Chest Med. 1989. PMID: 2567648 Review.
-
Bronchodilator reversibility in COPD.Chest. 2011 Oct;140(4):1055-1063. doi: 10.1378/chest.10-2974. Chest. 2011. PMID: 21972384 Review.
Cited by
-
Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients?Eur J Clin Pharmacol. 2003 Sep;59(5-6):449-55. doi: 10.1007/s00228-003-0614-2. Epub 2003 Aug 12. Eur J Clin Pharmacol. 2003. PMID: 12920494 Clinical Trial.
-
The Role of Pulmonary Function Testing in the Diagnosis and Management of COPD.Respir Care. 2023 Jul;68(7):889-913. doi: 10.4187/respcare.10757. Respir Care. 2023. PMID: 37353330 Free PMC article. Review.
-
Asthma outcomes: pulmonary physiology.J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S65-87. doi: 10.1016/j.jaci.2011.12.986. J Allergy Clin Immunol. 2012. PMID: 22386510 Free PMC article. Review.
-
Therapeutic Potential of Chungsangboha-tang for the Treatment of Asthma: A Review of Preclinical and Clinical Studies.J Clin Med. 2022 Jul 12;11(14):4035. doi: 10.3390/jcm11144035. J Clin Med. 2022. PMID: 35887796 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical